Literature DB >> 8866432

Post-infectious encephalitis with anti-galactocerebroside antibody subsequent to Mycoplasma pneumoniae infection.

M Nishimura1, T Saida, S Kuroki, T Kawabata, H Obayashi, K Saida, T Uchiyama.   

Abstract

Galactocerebroside (Gc) is a major component of myelin in both the peripheral and central nervous systems. Although it is regarded as an important glycolipid hapten of myelin in rabbit experimental allergic neuritis (EAN), its role in human demyelinating diseases is not known. We studied three post-infectious encephalitis (PIE) patients related to Mycoplasma pneumoniae infection. All three of three patients with encephalitis and M. pneumoniae infection were positive for Gc antibodies (100%), while 25% of 32 M. pneumoniae-infected patients without neurological disease were positive, and 3.8% of 52 healthy controls. This indicates anti-Gc antibody is induced by M. pneumoniae infection. One of the PIE patients, who had extraordinary high titer antibody to Gc, showed an extensive, diffuse white matter demyelination and poor recovery. Since circulating anti-Gc antibody induces central nervous system demyelination in animals with elevated antibody titers and disruption of the blood-brain barrier, anti-Gc antibody may have an important function in the increased demyelination in PIE patients after M. pneumoniae infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866432     DOI: 10.1016/0022-510x(96)00106-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  19 in total

1.  Cervical cord syndrome complicating pneumococcal pneumonia.

Authors:  Nissan Ben-Dov; Chen Hallevy; Yaniv Almog
Journal:  J Neurol       Date:  2002-09       Impact factor: 4.849

2.  Immune response to gangliosides in a case of Guillain-Barré syndrome after varicella.

Authors:  T Yoshikawa; K Suzuki; S Suga; E Miyata; H Yamamoto; T Hosokawa; T Kumagai; Y Asano
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

3.  Cross-reactivity of anti-galactocerebroside autoantibodies with a Trypanosoma brucei proteolipidic epitope.

Authors:  M Girard; S Bisser; P Buscher; B Bouteille; J L Preud'homme; M O Jauberteau
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

4.  Mycoplasma pneumoniae: Innocent Bystander or a True Cause of Central Nervous System Disease?

Authors:  Ari Bitnun; Susan E Richardson
Journal:  Curr Infect Dis Rep       Date:  2010-07       Impact factor: 3.725

Review 5.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  [Fulminant meningoencephalitis associated with Mycoplasma pneumoniae infection in adults. Aggressive treatment enabled a good outcome].

Authors:  Roland Sparing; Christoph Spitzer; Helga Häfner; Dirk Zolldann; Marcus H T Reinges; Timo Krings; Johannes Noth; Christoph M Kosinski
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214

Review 7.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

Review 8.  Molecular biology and pathogenicity of mycoplasmas.

Authors:  S Razin; D Yogev; Y Naot
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

9.  Immunostaining for oligodendrocyte-specific galactosphingolipids in fixed brain sections using the cholesterol-selective detergent digitonin.

Authors:  Yutaka Matsubayashi; Lena Iwai; Tomohisa Toda; Qing Richard Lu; Hiroshi Kawasaki
Journal:  J Neurosci Methods       Date:  2008-12-03       Impact factor: 2.390

10.  Reversible splenial lesion syndrome associated with acute Mycoplasma pneumoniae-associated encephalitis: A report of four cases and literature review.

Authors:  Xiaoyu Dong; Shuyan Cong
Journal:  Exp Ther Med       Date:  2018-07-02       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.